Novel Modulators of GABABR1a
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Nov 14, 2024
app pub date -
Aug 16, 2022
filing date -
Aug 16, 2022
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present invention relates to the field of disorders of the central and peripheral nervous system, in particular neurological and psychiatric disorders, and the prevention and/or treatment thereof. In particular, the present invention relates to the finding that short peptides derived from the soluble amyloid precursor protein α (sAPPα) bind and modulate GABABR1a. The peptides are provided for clinical use, more particularly for the treatment of neurological diseases such as CMT as well as for psychiatric disorders.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully